Fact CheckerSign in

NCT07556068Recruiting

Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation

Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation Monitoring: a Multicenter, Prospective, Observational Study

Source: ClinicalTrials.gov · Last updated 6 May 2026

Brief summary (registry, in English)

This multicenter, prospective, observational diagnostic accuracy study enrolls patients undergoing thrombectomy with intraoperative cerebral autoregulation monitoring and follows them up at predefined time points up to 90 days post-enrollment. The study aims to determine whether impaired cerebral autoregulation during thrombectomy can serve as an ultra-early biomarker for predicting futile recanalization in patients with acute ischemic stroke.

Status (registry)
Recruiting
Study type
Observational
Enrollment
129 (estimated)
First submitted
18 Apr 2026
Start date
20 Apr 2026
Primary completion date
15 Oct 2026
Lead sponsor
Beijing Shijitan Hospital, Capital Medical University
Diseases
Stroke
NCT number
NCT07556068

What you commit to

  • Study type: Observational
  • Planned participants: 129
  • From 20 Apr 2026 to the primary completion date, 15 Oct 2026
  • 4 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Untreated moderate or severe coronary artery stenosis, or previous coronary artery bypass surgery.
  • Current participation in another investigational drug or device study.

Other illness

  • Evidence of intracranial hemorrhage or hemorrhagic transformation before thrombectomy.
  • Known allergies or intolerances to antiplatelet agents, anticoagulation drugs, iodinated contrast and/or anesthetics.
  • Severe infection (e.g. sepsis) or multiple organ failure.
  • Refractory hypertension that is difficult to control by medication (Defined as persistent systolic blood pressure\>185 mmHg or diastolic blood pressure\>110 mmHg).
  • Malignant brain tumor or CNS infection.
  • Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations (e.g., dementia or mental illness)
  • local skin damage or other conditions that cannot cooperate with electrode sticking.
  • severe agitation or other conditions affecting data collection.

Lab values

  • Known hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency; oral anticoagulant therapy with INR \> 3; or use of a factor Xa inhibitor within the preceding 48 hours with an abnormal aPTT.
  • Baseline platelet count \< 50 × 10\^9/L.
  • Blood glucose concentration\<50 mg/dL (2.7 mmol/L) or \>400 mg/dL (22.2 mmol/L).
  • Severe cardiomyopathy with heart failure (LVEF ≤ 30% or NYHA class IV), acute myocardial infarction, or unstable angina.
  • Current hemodialysis or peritoneal dialysis; known severe renal insufficiency with estimated glomerular filtration rate \< 30 mL/min or serum creatinine \> 220 μmol/L (2.5 mg/dL).

Other

  • Baseline CT/MRI confirms the presence of multiple vascular territory acute strokes.
  • Baseline CT/MRI confirms the presence of arterial dissection.
  • Known intracranial aneurysm, and cerebral arteriovenous malformation.
  • Female who is pregnant or lactating at time of admission.
  • Anticipated life expectancy \< 6 months.

Who the study is looking for

  • Age ≥ 18
  • Clinical signs consistent with acute ischemic stroke with large vessel occlusion in the anterior circulation (intracranial segment of the internal carotid artery, middle cerebral artery M1 segment) demonstrated with CTA/MRA/DSA.
  • NIHSS score ≥ 6 obtained prior to endovascular treatment.
  • Modified Rankin Scale ≤ 1 prior to qualifying stroke.
  • Acute ischemic stroke, undergone endovascular treatment within 24 hours of onset (time of stroke is the last known normal for wake-up stroke or with unknown onset time).with reaching the goal of mTICI grade 2b-3
  • For patients with symptom onset within 6 hours: ASPECTS ≥ 3; for patients with symptom onset between 6 and 24 hours: age ≤ 80 years and ASPECTS ≥ 3.
  • Patient/Legally Authorized Representative has signed the Informed Consent Form.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (4)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Beijing Shijitan Hospital, Capital Medical University
Coordinator of this site? Confirm its status
BeijingChinaRecruiting
Dalian Municipal Central Hospital
Coordinator of this site? Confirm its status
DalianChinaNot yet recruiting
The First Affiliated Hospital of Harbin Medical University
Coordinator of this site? Confirm its status
HarbinChinaRecruiting
Weifang People's Hospital Affiliated to Weifang Medical University
Coordinator of this site? Confirm its status
WeifangChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.